Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Type 2 diabetic osteoporosis (T2DOP) is a complex metabolic bone disorder characterized by reduced bone density and increased risk of osteoporosis in patients with type 2 diabetes mellitus. The etiology of T2DOP is multifactorial, involving hyperglycemia, insulin resistance, and gut microbiota dysbiosis. Current management strategies for T2DOP typically involve a comprehensive approach, including strict glycemic control, vitamin D and calcium supplementation, anti-osteoporotic medications, increased physical activity, and gut microbiota modulation. This study aimed to investigate the therapeutic potential of the combination of Dasatinib and Quercetin (D + Q), known as senolytics, in treating T2DOP. To elucidate the underlying mechanisms, a well-characterized T2DOP mouse model was established. Bone mass was evaluated using micro-computed tomography and histological staining techniques. Subsequently, the impact of D + Q treatment on gut microbiota composition and complex serum metabolite profiles was comprehensively examined. The results demonstrated that D + Q reshaped gut microbiota, resulting in increased short-chain fatty acid producers (Lachnospiraceae and Bacteroides) and decreased proinflammatory bacteria (Mucispirillum), which were associated with the therapeutic effects in bone-fat balance. Additionally, D + Q treatment enhanced amino acid and short-chain fatty acid metabolism while simultaneously reducing cholesterol and triglyceride levels.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome
- Date Crossref
- 03/09/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Guangzhou University of Chinese Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Guangdong Provincial Hospital of Traditional Chinese Medicine pays non établi dans la noticeÉtablissement de santé
-
Guangdong Academy of Medical Sciences pays non établi dans la noticeÉtablissement de santé
-
Guangdong Provincial Academy of Chinese Medical Sciences Bone and Joint Research Team of Degeneration and Injury pays non établi dans la noticeOrganisation à but non lucratif
-
Fifth School of Clinical Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine pays non établi dans la noticeStructure de recherche
-
Guangdong Provincial Second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine) pays non établi dans la noticeStructure de recherche
-
First School of Clinical Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases pays non établi dans la noticeStructure de recherche
Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine et Guangdong Academy of Medical Sciences, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.